Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
about
Heart failure with preserved ejection fraction: emerging drug strategiesInequity of access to ACE inhibitors in Swedish heart failure patients: a register-based studyHeart failure and Alzheimer's diseaseAssociation between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction.Renin-Angiotensin System Inhibitor is Associated with Lower Risk of Ensuing Chronic Kidney Disease after Functional Recovery from Acute Kidney Injury.Update on heart failure with preserved ejection fraction.Pharmacological Treatment of Heart Failure with Preserved Ejection FractionDipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Brain natriuretic peptide is a potent vasodilator in aged human microcirculation and shows a blunted response in heart failure patients.Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II.Emerging role of liver X receptors in cardiac pathophysiology and heart failure.Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]).Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.Contemporary strategies in the diagnosis and management of heart failureCardiac resynchronization therapy in CKD: a systematic reviewCurrent treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions.Targeting the renin-angiotensin-aldosterone system in heart failure.Renin-angiotensin system blocking drugs.Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.Modulation of the renin-angiotensin-aldosterone system in heart failure.Heart failure with preserved ejection fraction: a clinical dilemma.Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review.Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry.Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies.The effect of angiotensin II microinjection into the bed nucleus of the stria terminalis on serum lipid peroxidation and nitric oxide metabolite levels.Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease study and the Cockcroft-Gault equation in patients with heart failure.Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study.New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy.Renal Response in Patients with Chronic Kidney Disease Predicts Outcome Following Cardiac Resynchronization Therapy.Age, prognostic impact of QRS prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14,713 patients in the Swedish Heart Failure Registry.Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.Chronic heart failure management in primary healthcare in Poland: Results of a nationwide cross-sectional study.Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.N-terminal pro-brain natriuretic peptide is a useful marker to identify latent heart failure patients in older adults in a rural outpatient clinic.
P2860
Q24595118-1FE6A36C-45F0-4C36-A8EF-0F723B36BAE4Q26799578-BEF920CA-520D-4473-9F75-F450CAB905FBQ26852526-312DA066-9807-4E6E-BAA3-8A2F4BC383B8Q33164540-F93CC3F3-3AFA-4935-B7AC-8091C33824F3Q33559888-E370BE42-5144-4DBA-94BE-1991FDBA676DQ33640339-17D6190E-7791-42C0-AE95-12C048C3BDA4Q33885952-8DD65C3C-66B1-45DF-B5EE-BCFE1BEAA410Q34027687-A9F070F2-EE24-4764-82C0-D62DB8DE9845Q34375466-9E4F2B5F-2BC7-45DB-8521-23BD5FDEFE88Q35153293-0540CFE9-6203-4D80-9C76-F019160A8E69Q35738903-230A59A6-0AD7-40D9-8648-C72FAFD1BA2BQ35792547-35D66CBF-FBE1-43F1-A22E-0378A8D6F7FEQ36114343-C54FB2B3-7A24-4321-AD4C-2EED65542BBDQ36322805-5854B516-E78F-4A89-84F6-944EFC5A1E9BQ36807898-EC1D0E14-3995-4AB4-B8F8-1D038570BCEDQ36851454-EEFDE8EE-26B4-4089-AB81-5B35053C89ABQ36877666-1A390BB8-AD4A-43EC-941A-A28ACF54C2DFQ37041145-7FBF6982-C32F-4178-9F10-08D7434C3624Q37065585-631153F1-F587-41E3-A0B1-A1EEA3A04719Q37292234-B2D9903A-4ABF-4DD7-ADE7-48FC7F181CD2Q37710165-85F25D62-8063-46AE-904B-BA7456734318Q38074092-926E52FD-BC3D-4328-B2EF-15BC18F93BA8Q38137851-B36C618A-854B-4223-A5A5-31BD2A341ED1Q38162791-F82DD68B-A547-44AA-A089-14781DB129BFQ38186633-B250620A-27C5-4097-B035-16389350D19BQ38195149-D6628364-8A30-4EF2-8856-B120CD18DC66Q38593070-24127683-4A81-4E0D-BAC1-63F8B4D98203Q38658569-E063FF5F-C77E-4C16-9B68-FE1E9D31FBA3Q38972837-C2963561-52F1-4BDA-B480-6FE01F6EA2B3Q39432098-45BBFA9C-1CC0-47D6-9786-A98C4BD6248EQ39634108-2FDE038A-0FBF-439B-B6D6-16328793009FQ40100257-EBB33687-A862-4D7D-9B21-6C248B976476Q40322592-218B127A-84F7-41E9-A142-4A289E899A54Q40684670-836C3308-B71E-4D61-AB5B-462B1E512151Q40731837-79AEB172-EE15-4817-B6D4-CAF7D828CA0FQ43998937-183E66CE-14B9-441F-852B-FEAB36A966F7Q46874079-352657DC-75F8-48F9-BDA4-B5E6E3122C24Q47429906-F44D1F42-AA52-4839-8714-54A33700991BQ47890686-1B1FA5D2-5508-4C22-A863-7A3C1BE6C420Q48425322-91DB79C8-1699-4078-B18F-4F1467DA9979
P2860
Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Association between use of ren ...... d preserved ejection fraction.
@en
Association between use of ren ...... d preserved ejection fraction.
@nl
type
label
Association between use of ren ...... d preserved ejection fraction.
@en
Association between use of ren ...... d preserved ejection fraction.
@nl
prefLabel
Association between use of ren ...... d preserved ejection fraction.
@en
Association between use of ren ...... d preserved ejection fraction.
@nl
P2093
P356
P1476
Association between use of ren ...... nd preserved ejection fraction
@en
P2093
Lars H Lund
Magnus Edner
Ulf Dahlström
P304
P356
10.1001/JAMA.2012.14785
P407
P50
P577
2012-11-01T00:00:00Z